Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
A method is disclosed of predicting cancer patient response to immune checkpoint inhibitors, e.g., an antibody drug blocking ligand activation of programmed cell death 1 (PD-1) or CTLA4. The method includes obtaining mass spectrometry data from a blood-based sample of the patient, obtaining integrated intensity values in the mass spectrometry data of a multitude of pre-determined mass-spectral features; and operating on the mass spectral data with a programmed computer implementing a classifier. The classifier compares the integrated intensity values with feature values of a training set of class-labeled mass spectral data obtained from a multitude of melanoma patients with a classification algorithm and generates a class label for the sample. A class label \"early\" or the equivalent predicts the patient is likely to obtain relatively less benefit from the antibody drug and the class label \"late\" or the equivalent indicates the patient is likely to obtain relatively greater benefit from the antibody drug.
Roder; Joanna (Steamboat Springs, CO), Meyer; Krista (Steamboat Springs, CO), Grigorieva; Julia (Steamboat Springs, CO), Tsypin; Maxim (Steamboat Springs, CO), Oliveira; Carlos (Steamboat Springs, CO), Steingrimsson; Arni (Steamboat Springs, CO), Roder; Heinrich (Steamboat Springs, CO), Asmellash; Senait (Denver, CO), Sayers; Kevin (Denver, CO), Maher; Caroline (Denver, CO), Weber; Jeffrey (New York, NY)
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.